About Our Company / About CardioFocus

Dr. Amirana has a unique combination of operating and venture capital experience in both medtech and pharma/biotech and has cross fertilized various disciplines throughout his career. He has served as an operator, board member and investor since 2005 and prior to that was in operating roles. He currently serves as CEO of LuxMed Systems. He most recently managed the life sciences portfolio at Allied Minds, an investment / IP commercialization vehicle which is publicly listed on the London Stock Exchange. Prior to that he was a Partner at Oxford BioScience Partners where he sourced deals, led investments and served on numerous boards. His investing and operating experience covers medical devices, drug discovery and healthcare IT/data analytics. Omar has served on over 20 boards and has participated in over $1billion of capital raises and transactions. Prior to his ~14 years in venture capital, he served in Silicon Valley for 11 years where he co-founded or held varying operating roles in 4 life sciences startups (3 went public on NASDAQ). He participated in an IPO roadshow for an electrophysiology company he co-founded, Cardima, which was a spin-off of Target Therapeutics and was funded by Kleiner Perkins and NEA. After Silicon Valley, he served as VP of Business Development for the electrophysiology business unit at St Jude Medical (STJ; now Abbott) in Minneapolis, MN while managing an advanced development group of ~20 engineers. Omar has worked with numerous investors, Scientific Advisory Boards, inventors and investigators. He is an inventor on numerous issued patents and is passionate about the intersection of life sciences and technology. Omar loves the beach, basketball, golf, paddle ball, the outdoors, travel and spending precious time with his wife, daughters, family and dog.

Mr. Barrett joined CardioFocus in 2002 and currently serves as Chief Executive Officer (CEO) & President, leveraging over 30 years of medical device industry experience into the role of CEO. During his more than 15 years with the company has held roles of increasing responsibility from Vice President through to CEO & President.  Previously, Mr. Barrett was Vice President of Clinical Operations at Cyberkinetics Neurotechnology Systems, Inc., a public medical device company that achieved first-in-man success in novel, implantable brain-computer interfaces. He also served at Cyberonics as the Vice President, Business and Technology Development. Previously, Mr. Barrett held positions in business development, clinical & regulatory affairs, and quality auditing at Biofield Corporation, Dornier Medical Systems, and Bausch & Lomb.  From 2010-2013 he served as the industry representative on the FDA’s Circulatory Systems Device Advisory Panel. He received bachelor’s degrees in chemical engineering and chemistry from Syracuse University and a Master of Business Administration from Kennesaw University in Atlanta.

Mr. Larsen is a co-founder and Managing Director of Accuitive Medical Ventures. He brings over 45 years of operating experience, as well as expansive technical understanding and experience in the medical device industry. Mr. Larsen was a co-founder of Novoste Corporation, where his efforts as a director and executive were critical to its ultimate success. Mr. Larsen also co-founded The Innovation Factory, through his role at TIF, Mr. Larsen has co-founded numerous companies including: Acufocus, AqueSys, Halscion, LipoSonix, Neuronetics and Sebacia. He holds over 30 issued U.S. and international patents on medical devices.

As Managing Director of H.I.G. BioHealth Partners, Dr. Robertson focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Dr. Robertson has been active in the life sciences sector for more than 30 years. Dr. Robertson currently serves on the boards of Apollo Endosurgery, RxSight, CardioFocus, Clarus Therapeutics, Iconic Therapeutics, Exagen, Zerigo Health, and Augmedics. Prior to joining H.I.G., he served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on life science investments. While at Toucan, Dr. Robertson invested in leading drug and device companies throughout the U.S. Prior to Toucan, he was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his private equity career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies.

Dr. Robertson holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.

Gwen is a Managing Director of H.I.G. BioHealth Partners, focusing on investment opportunities in the life sciences sector, including biopharmaceuticals, health care IT, medical devices, and diagnostics.

Gwen has been active in the life sciences sector for more than 28 years. Previously, she served as the General Manager and Vice President of US Robotics for Smith and Nephew and as the Corporate Vice President of Global Corporate Development, Strategy and Strategic Relationships at Teleflex where for eight years she presided over all global acquisitions. Gwen joined Teleflex as a result of Teleflex’s acquisition of Hotspur Technologies, a company Gwen co-founded and served as President and Chief Executive Officer. Gwen was also a co-founder of Nellix Endovascular, Bacchus Vascular and AneuRx, all three of which were medical device companies later acquired by larger strategic players. In addition, Gwen has been general partner of several private equity entities.

Gwen holds an M.S. in Mechanical Engineering from Stanford University, as well as an MBA from Harvard Business School. She also holds a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology where she simultaneously completed her pre-med requirements.

Mr. Wethington is a serial CEO and entrepreneur. He has been involved with a unique list of “market innovation firsts” to tackle some of the leading chronic diseases of our time. Mr. Wethington has had four consecutive M&A exits (Medtronic, St. Jude Medical, Gambro and CryoLife), two as a CEO and two as a global market/commercial lead, and has had a fundraise plus exit value generation track record now approaching over $1 billion (venture, IPO and strategic fundraise-exit). Rounding out this experience, Mr. Wethington has for profit (private and public co.) and not-for-profit independent board member, audit committee chair, oversight committee member, strategic advisor, mentor and leadership experience at medical device, digital healthcare, and academic based organizations. Five years before the Covid-19 pandemic, Mr. Wethington started, co-invented and led the world’s first percutaneous neuromodulation stimulation device company to help wean patients off ventilators ($11.5B total addressable market TAM). Along with other ventures, Mr. Wethington is currently developing and forming a cardiac diagnostic company. Mr. Wethington serves as an Oversight Committee Member on the Technology and Validation Program Committee at Case Western Reserve University, and a mentor for Pre- and Post-Doctoral Biomedical Research Students enrolled in an NIH-funded EB4 program hosted by Washington University. Mr. Wethington currently serves as a strategic advisor for a publicly traded respiratory company.

Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential. Aurora’s investment team has the experience, strategic relationships and capital to help companies accelerate their growth and gain a strong competitive advantage in their market space. Since its founding in 1994, Aurora has invested in over 60 portfolio companies, resulting in five IPOs and eight M&A transactions.

BioMed Ventures is the strategic investment arm of BioMed Realty. Acquired by Blackstone in 2016, BioMed Realty is the leading provider of real estate solutions to the life science industry – providing leasing, development, construction, redevelopment, acquisition, financing and property management to clients in the United States and United Kingdom, with over 12 million square feet of rentable space worldwide.

Fletcher Spaght Ventures, (FSV) is a balanced-stage venture capital firm investing in high growth opportunities in healthcare/life sciences and related information technology companies. FSV was established in 2001 by Fletcher Spaght, Inc. (FSI), a strategy consulting firm founded in 1983. The FSI:FSV collaboration provides key differentiation from other venture capital firms and allows for significant advantages in deal sourcing and investing.

With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Its seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. It invests in companies developing novel products for significant unmet medical needs.

Kestrel Management invests in early stage healthcare companies. Investments other than CardioFocus include Health Dialog (disease management), PHT Corp. (Clinical trial support), Iora Healthcare (patient centric primary care), and Constant Therapy (digital solutions to brain injury). Kestrel typically invests at the pre-revenue stage and partners with both angels and venture capital firms.

SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm. Its goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over $2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.